What people are saying - Write a review
We haven't found any reviews in the usual places.
Trend Analysis of IND Submissions in Nine Therapeutic Areas 19631989
Analysis of Biotechnology Medicines and Vaccines in U S Development
16 other sections not shown
Other editions - View all
Analysis ANDA Annual Anti-Infective antihistamine biologics Biopharmaceuticals Biotech Biotechnology Boston Consulting Group Bristol-Myers Squibb Cancer Cardiovascular CBER CDER Centre for Medicines chemical entities clinical development clinical research Clinical Trials compounds cost countries Development Projects DiMasi diseases Drug Approval Drug Development Endocrine estimate FDA 1st action FDA 2nd FDA review firms FY94 cohort Genentech Glaxo Wellcome hours oral includes IND filing Indication and Phase International Japan Lasagna Lasagna Tufts Center Median Medicines Research Merck million NCEs NDA approval NDA submission Neuropharmacological Drug NMEs Number Oncology Oncology and Pulmonary Orphan Drug patient percent Pfizer pharmaceutical companies Pharmaceutical Industry Pharmaceutical R&D Pharmaceutical Research Pharmacoeconomic Phase Phase Phase PhRMA Priority Product Development Index Projects by Indication protocol Pulmonary Drug Products R&D Spending Report Research and Development Resubmissions Selected R&D Notes Source Sponsor response Study of Drug Success Rates Costs/Complexity Supplements survey therapeutic areas Therapeutic Category thought leader Total U.S. DEVELOPMENT